These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 9614724)

  • 81. Characterization of MRI response to treatment with interferon beta-1b: contrast-enhancing MRI lesion frequency as a primary outcome measure.
    Stone LA; Frank JA; Albert PS; Bash CN; Calabresi PA; Maloni H; McFarland HF
    Neurology; 1997 Sep; 49(3):862-9. PubMed ID: 9305355
    [TBL] [Abstract][Full Text] [Related]  

  • 82. The interferon-beta 1b clinical trial and its implications for other trials.
    Paty DW
    Ann Neurol; 1994; 36 Suppl():S113-4. PubMed ID: 8017869
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Interferon-beta treatment of human disease.
    Alam JJ
    Curr Opin Biotechnol; 1995 Dec; 6(6):688-91. PubMed ID: 8527841
    [TBL] [Abstract][Full Text] [Related]  

  • 84. The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b.
    Rice GP; Paszner B; Oger J; Lesaux J; Paty D; Ebers G
    Neurology; 1999 Apr; 52(6):1277-9. PubMed ID: 10214759
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. 1997.
    Rudick RA; Goodkin DE; Jacobs LD; Cookfair DL; Herndon RM; Richert JR; Salazar AM; Fischer JS; Granger CV; Simon JH; Alam JJ; Simonian NA; Campion MK; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Pullicino PM; Scherokman BJ; Weistock-Guttman B; Whitham RH;
    Neurology; 2001 Dec; 57(12 Suppl 5):S25-30. PubMed ID: 11902591
    [No Abstract]   [Full Text] [Related]  

  • 86. The treatment of multiple sclerosis: current and future.
    Polman CH; Hartung HP
    Curr Opin Neurol; 1995 Jun; 8(3):200-9. PubMed ID: 7551119
    [TBL] [Abstract][Full Text] [Related]  

  • 87. A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barré syndrome.
    Pritchard J; Gray IA; Idrissova ZR; Lecky BR; Sutton IJ; Swan AV; Willison HJ; Winer JB; Hughes RA
    Neurology; 2003 Nov; 61(9):1282-4. PubMed ID: 14610140
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Blood levels of transforming growth factor-beta 1 (TGF-beta1) are elevated in both relapsing remitting and chronic progressive multiple sclerosis (MS) patients and are further augmented by treatment with interferon-beta 1b (IFN-beta1b).
    Nicoletti F; Di Marco R; Patti F; Reggio E; Nicoletti A; Zaccone P; Stivala F; Meroni PL; Reggio A
    Clin Exp Immunol; 1998 Jul; 113(1):96-9. PubMed ID: 9697990
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Key issues in the diagnosis and treatment of multiple sclerosis. An overview.
    O'Connor P;
    Neurology; 2002 Sep; 59(6 Suppl 3):S1-33. PubMed ID: 12448786
    [No Abstract]   [Full Text] [Related]  

  • 90. Designing rational therapies for multiple sclerosis.
    Steinman L; Conlon P
    Biotechnology (N Y); 1995 Feb; 13(2):118-20. PubMed ID: 9678929
    [No Abstract]   [Full Text] [Related]  

  • 91. The effects of intramuscular interferon beta-Ia in patients at high risk for development of multiple sclerosis: a post hoc analysis of data from CHAMPS.
    O'Connor P;
    Clin Ther; 2003 Nov; 25(11):2865-74. PubMed ID: 14693310
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Multiple sclerosis: new therapeutic concepts or better use of old drugs?
    Clanet M
    Eur Neurol; 1993; 33(6):401-2. PubMed ID: 8307059
    [No Abstract]   [Full Text] [Related]  

  • 93. Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b.
    Antonelli G; Simeoni E; Bagnato F; Pozzilli C; Turriziani O; Tesoro R; Di Marco P; Gasperini C; Fieschi C; Dianzani F
    J Neurol Sci; 1999 Oct; 168(2):131-6. PubMed ID: 10526196
    [TBL] [Abstract][Full Text] [Related]  

  • 94. The significance of neutralizing antibodies in patients with multiple sclerosis treated with interferon beta.
    Rice G
    Arch Neurol; 2001 Aug; 58(8):1297-8. PubMed ID: 11493173
    [No Abstract]   [Full Text] [Related]  

  • 95. Interferon-beta treatment decreases cholesterol plasma levels in multiple sclerosis patients.
    Morra VB; Coppola G; Orefice G; De Michele G; Vacca G; Filla A; Bonavita V
    Neurology; 2004 Mar; 62(5):829-30. PubMed ID: 15007146
    [No Abstract]   [Full Text] [Related]  

  • 96. Subcutaneous recombinant interferon-beta-1a (Rebif): a review of its use in relapsing-remitting multiple sclerosis.
    Murdoch D; Lyseng-Williamson KA
    Drugs; 2005; 65(9):1295-312. PubMed ID: 15916455
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Interferon beta treatment for multiple sclerosis: persisting questions.
    Goodkin DE
    Mult Scler; 1996 Jul; 1(6):321-4. PubMed ID: 9345408
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Interferon beta-1a for optic neuritis patients at high risk for multiple sclerosis.
    CHAMPS Study Group
    Am J Ophthalmol; 2001 Oct; 132(4):463-71. PubMed ID: 11589865
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Interferon beta in multiple sclerosis. Some form of compromise must be accepted.
    Peltola J; Keranen T
    BMJ; 1997 Feb; 314(7080):602. PubMed ID: 9055733
    [No Abstract]   [Full Text] [Related]  

  • 100. Multiple sclerosis: combination therapy in MS--still a valid strategy.
    Kieseier BC; Stüve O
    Nat Rev Neurol; 2011 Oct; 7(12):659-60. PubMed ID: 22009284
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.